<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011334</url>
  </required_header>
  <id_info>
    <org_study_id>ML28700</org_study_id>
    <nct_id>NCT02011334</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.</brief_title>
  <official_title>A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and&#xD;
      efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease&#xD;
      modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis patients in Latin America with&#xD;
      an inadequate response to non-biologic DMARDs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) Remission Rate</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events (AE)</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in DAS28-ESR</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: ACR/EULAR responses</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in disease activity (CDAI/SDAI)</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in joint swelling/tenderness (SJC/TJC)</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Assessment of immunogenicity</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: DAS28-ESR Remission Rate</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of patients who maintain DAS28 Remission/LDA</measure>
    <time_frame>From Week 24 to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Rates of AE leading to dose modification or study withdrawal</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Assessment of physical examination and vital signs</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of clinically significant laboratory abnormalities following treatment</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RoActemra/Actemra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab [RoActemra/Actemra]</intervention_name>
    <description>162 mg will be administered once weekly by subcutaneous injection.</description>
    <arm_group_label>RoActemra/Actemra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;/= 18 years of age.&#xD;
&#xD;
          -  Patients with a diagnosis of active RA according to the revised (1987) ACR criteria or&#xD;
             EULAR/ACR (2010) criteria.&#xD;
&#xD;
          -  Patients with moderate to severe RA (DAS-ESR 28 &gt;/= 3.2).&#xD;
&#xD;
          -  Receiving non-study treatment on an outpatient basis.&#xD;
&#xD;
          -  Oral corticosteroids (&lt;/= 10 mg/day prednisone or equivalent), NSAIDs and non-biologic&#xD;
             DMARDs are permitted if on a stable dose regimen for &gt;/= 4 weeks prior to Baseline.&#xD;
&#xD;
          -  Inadequate response to previous non-biologic DMARD therapy.&#xD;
&#xD;
          -  Use of effective contraception throughout the study as defined by protocol; female&#xD;
             patients of childbearing potential cannot be pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant medical conditions.&#xD;
&#xD;
          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic&#xD;
             ulcerative lower GI disease that might predispose to perforation.&#xD;
&#xD;
          -  Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other&#xD;
             infections.&#xD;
&#xD;
          -  Any infection requiring hospitalization or treatment with IV antibiotics within 4&#xD;
             weeks of Screening or oral antibiotics within 2 weeks of Screening.&#xD;
&#xD;
          -  Clinically significant findings on lab tests and/or hepatits B or C, or HIV&#xD;
             screenings.&#xD;
&#xD;
          -  Active TB requiring treatment within the previous 3 years.&#xD;
&#xD;
          -  Evidence of active malignant disease, malignancies diagnosed within the previous 10&#xD;
             years, or breast cancer diagnosed within the previous 20 years.&#xD;
&#xD;
          -  History of alcohol, drug, or chemical abuse within 1 year prior to Screening.&#xD;
&#xD;
          -  Neuropathies or other conditions that might interfere with pain evaluation.&#xD;
&#xD;
          -  Major surgery (including joint surgery) within 8 weeks prior to Screening or planned&#xD;
             major surgery within 6 months following Baseline.&#xD;
&#xD;
          -  Rheumatic autoimmune disease other than RA, including systemic lupus erythematosis,&#xD;
             mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic&#xD;
             involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's&#xD;
             syndrome). Secondary Sj√∂gren's syndrome with RA is permitted.&#xD;
&#xD;
          -  Functional Class IV as defined by the ACR Classification of Functional Status&#xD;
             in-Rheumatoid Arthritis (Appendix 2).&#xD;
&#xD;
          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of&#xD;
             16.&#xD;
&#xD;
          -  Prior history of or current inflammatory joint disease other than RA.&#xD;
&#xD;
          -  Previous exposure to RoActemra/Actemra (either IV or SC).&#xD;
&#xD;
          -  Prior treatment with a biologic agent.&#xD;
&#xD;
          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the&#xD;
             investigational drug, whichever is longer) of Screening.&#xD;
&#xD;
          -  Previous treatment with any cell-depleting therapies, including investigational agents&#xD;
             or approved therapies, with alkylating agents such as chlorambucil, or with total&#xD;
             lymphoid irradiation.&#xD;
&#xD;
          -  Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.&#xD;
&#xD;
          -  Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428DQG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>C. A. B. A.</city>
        <zip>C1055AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74110010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <zip>36036-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuiaba</city>
        <state>MT</state>
        <zip>78025-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20950-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04026-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota D.C.</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Domingo</city>
        <zip>10208</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maracaibo</city>
        <zip>4001</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Punto Fijo</city>
        <zip>4102</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Dominican Republic</country>
    <country>Mexico</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Ecuador</country>
    <country>Uruguay</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

